Company Overview and News

 
Tech Expert on Challenges of IIoT in Oil and Gas

2018-10-05 rigzone
As the oil and gas industry opens itself to newer technologies to make operations more efficient, roadblocks are par for the course.
CPGX CGGXP

2
TransCanada Vends $484M Renewable Energy Assets to Trim Debt

2018-08-06 zacks
TransCanada Corporation (TRP - Free Report) recently inked a deal to do away with its wind energy portfolio for C$630 (or $484) million, in a bid to slash its huge debt which currently stands at around C$35 billion. The agreement will help TransCanada raise capital, which can be deployed into more traditional assets like oil and gas pipelines.
ECR ENBBF TRP ENB BCEI FUN BGSF INGXF SE ENB CPGX TRP EBBNF CGGXP

7
TransCanada: Strong Prospects For 10% Dividend Growth

2018-06-21 seekingalpha
TransCanada is one of the largest pipeline operators in North America and is far more than just the Keystone Pipeline.
TRP CPGX AMID TRP CGGXP

1
Columbia Pipeline Group Reaches 99.5 Percent Availability With PlantPAx DCS

2018-05-07 worldoil
World Oil TechTalk allows marketers to connect directly with the World Oil audience by enabling them to create content and participate in the conversation on the World Oil website. Each TechTalk article is produced by the marketer.
CPGX ROK CGGXP

1
MRC Global (MRC) Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Greetings and welcome to the MRC Global First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.
CPGX MRC CGGXP

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 198280959